Foundation Institute G.Giglio
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Grimaldi, Luigi
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NCT06220669: A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Recruiting
2
200
Europe, US, RoW
LY3541860, Placebo
Eli Lilly and Company
Multiple Sclerosis
08/27
08/28
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Active, not recruiting
2
367
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
11/26
11/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
READAPT, NCT05476081: A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA

Completed
N/A
2239
Europe
Aspirin, B01AC06, acetylsalicylic acid, Clopidogrel, B01AC04, Ticagrelor, B01AC24
University of L'Aquila
Ischemic Stroke, TIA
02/23
05/23
ALIGNED, NCT06935578: RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases

Recruiting
N/A
500
Europe
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
CADASIL, CADASIL (Diagnosis), Moya Moya Disease, Moyamoya, Moyamoya Syndrome, Sneddon Syndrome, Fabry Disease, COL4A1\2
05/25
11/25
COGNIKET-MCI, NCT06347315: Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment

Recruiting
N/A
380
Europe
BrainXpert, Placebo
Société des Produits Nestlé (SPN)
Mild Cognitive Impairment
12/27
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Grimaldi, Luigi
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NCT06220669: A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Recruiting
2
200
Europe, US, RoW
LY3541860, Placebo
Eli Lilly and Company
Multiple Sclerosis
08/27
08/28
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Active, not recruiting
2
367
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
11/26
11/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
READAPT, NCT05476081: A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA

Completed
N/A
2239
Europe
Aspirin, B01AC06, acetylsalicylic acid, Clopidogrel, B01AC04, Ticagrelor, B01AC24
University of L'Aquila
Ischemic Stroke, TIA
02/23
05/23
ALIGNED, NCT06935578: RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases

Recruiting
N/A
500
Europe
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
CADASIL, CADASIL (Diagnosis), Moya Moya Disease, Moyamoya, Moyamoya Syndrome, Sneddon Syndrome, Fabry Disease, COL4A1\2
05/25
11/25
COGNIKET-MCI, NCT06347315: Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment

Recruiting
N/A
380
Europe
BrainXpert, Placebo
Société des Produits Nestlé (SPN)
Mild Cognitive Impairment
12/27
12/27

Download Options